ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis

Cytometry B Clin Cytom. 2006 Jul 15;70(4):235-41. doi: 10.1002/cyto.b.20121.

Abstract

Background: The clinical course of chronic lymphocytic leukaemia (CLL) is variable. ZAP-70 expression is believed to provide prognostic information. The flow cytometric detection of ZAP-70 is difficult because it is an intracellular antigen with weak expression in CLL. Consensus has not been reached as to the best method for measurement.

Methods: We analyzed 72 CLL patient samples for ZAP-70 expression and IgVH mutational status. Sensitivity and specificity of ZAP-70 expression against IgVH mutational status were assessed for two clones (2F3.2 and 1E7.2) and for four methods of analysis: percentage positivity (PP), comparing test to isotype control, ratio of geometric means of test and isotype control, and percentage and ratiometric methods comparing test and T/NK cell populations. The effects of anticoagulant, collection times, and time to analysis were also evaluated.

Results: Sensitivity and specificity were 85 and 88%, respectively, for Upstate PP; 70 and 88% for Caltag PP; 89 and 91% for Upstate ratio; 89 and 88% for Caltag ratio. Intraobserver variability was smaller when ZAP-70 expression was assessed using a ratiometric approach rather than the percentage method. By 48 h, we observed an average decrease of 13% in the Caltag ratio in the heparin preserved samples compared to an increase of 3% in those collected in EDTA. Within the first 24-h period, a greater percent variability was observed in those samples collected into EDTA compared with heparin.

Conclusion: Our data support a rapid method for ZAP-70 measurement using commercially available fixation/permeabilization reagents, a conjugated antibody, and a ratiometric method of analysis that minimizes subjective interpretation of the results. This is a method of ZAP-70 assessment that could be included in a routine diagnostic CLL panel; however, the choice of anticoagulant and time of analysis after collection are critical factors in accurate assessment of ZAP-70 expression.

Publication types

  • Comparative Study

MeSH terms

  • Antibodies / immunology*
  • Anticoagulants / pharmacology*
  • Antigen-Antibody Reactions
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / chemistry
  • Biomarkers, Tumor / immunology
  • Disease Progression
  • Flow Cytometry / methods*
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Immunoglobulin Variable Region / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • Middle Aged
  • Mutation
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Staining and Labeling
  • Time Factors
  • ZAP-70 Protein-Tyrosine Kinase / analysis*
  • ZAP-70 Protein-Tyrosine Kinase / drug effects
  • ZAP-70 Protein-Tyrosine Kinase / immunology

Substances

  • Antibodies
  • Anticoagulants
  • Biomarkers, Tumor
  • Immunoglobulin Heavy Chains
  • Immunoglobulin Variable Region
  • ZAP-70 Protein-Tyrosine Kinase
  • ZAP70 protein, human